MedPath

ASTELLAS PHARMA US, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.astellas.com/us

Clinical Trials

13

Active:12
Completed:1

Trial Phases

2 Phases

Phase 1:6
Not Applicable:1

Drug Approvals

13

FDA:13

Drug Approvals

IZERVAY

Approval Date
Feb 1, 2024
FDA

CRESEMBA

Approval Date
Dec 8, 2023
FDA

Xtandi

Approval Date
Nov 20, 2023
FDA

VEOZAH

Approval Date
Oct 18, 2023
FDA

Prograf

Approval Date
Aug 25, 2023
FDA

ASTAGRAF XL

Approval Date
Aug 25, 2023
FDA

VESIcare

Approval Date
Oct 31, 2022
FDA

VESIcare

Approval Date
Oct 31, 2022
FDA

Mycamine

Approval Date
Aug 4, 2022
FDA

Myrbetriq

Approval Date
Jul 13, 2022
FDA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (85.7%)
Not Applicable
1 (14.3%)
No trials found

News

FDA Issues Black Box Warning for Fezolinetant (Veozah) Due to Liver Injury Risk

The FDA issued a black box warning for fezolinetant (Veozah) due to rare but serious liver injury risks associated with the drug.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy